Evidence map›Paper›PMID 33614978›Full record

ArticleHealth science reports2021

The performance of hepatitis C virus (HCV) antibody point-of-care tests on oral fluid or whole blood and dried blood spot testing for HCV serology and viral load among individuals at higher risk for HCV in South Africa.

Nishi Prabdial-Sing, Lucinda Gaelejwe, Lillian Makhathini, Jayendrie Thaver, Morubula Jack Manamela, Susan Malfeld, C Wendy Spearman, Mark Sonderup, Andrew Scheibe, Katherine Young and 2 more

Open access · goldAbstract read
In one paragraph

Article in Health science reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Dried Blood Spot: A Tool to Ensure Broad Access to Hepatitis D Screening, Diagnosis, and Treatment Monitoring.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Nishi Prabdial-SingCentre for Vaccines and Immunology National Institute for Communicable Diseases Johannesburg South Africa.ORCID https://orcid.org/0000-0002-5300-0245
Lucinda GaelejweCentre for Vaccines and Immunology National Institute for Communicable Diseases Johannesburg South Africa.
Lillian MakhathiniCentre for Vaccines and Immunology National Institute for Communicable Diseases Johannesburg South Africa.
Jayendrie ThaverCentre for Vaccines and Immunology National Institute for Communicable Diseases Johannesburg South Africa.
Morubula Jack ManamelaCentre for Vaccines and Immunology National Institute for Communicable Diseases Johannesburg South Africa.
Susan MalfeldCentre for Vaccines and Immunology National Institute for Communicable Diseases Johannesburg South Africa.
C Wendy SpearmanDivision of Hepatology, Department of Medicine, Faculty of Health Sciences University of Cape Town Cape Town South Africa.
Mark SonderupDivision of Hepatology, Department of Medicine, Faculty of Health Sciences University of Cape Town Cape Town South Africa.
Andrew ScheibeTB HIV Care Cape Town South Africa.
Katherine YoungTB HIV Care Cape Town South Africa.
Harry HauslerTB HIV Care Cape Town South Africa.
Adrian J PurenCentre for Vaccines and Immunology National Institute for Communicable Diseases Johannesburg South Africa.
National Health Laboratory Service · ZATB HIV Care Association · ZAUniversity of Cape Town · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsTo enhance screening and diagnosis in those at-risk of hepatitis C virus (HCV), efficient and improved sampling and testing is required. We investigated the performance of point-of-care (POC) tests and dried blood spots (DBS) for HCV antibody and HCV RNA quantification in individuals at higher risk for HCV (people who use and inject drugs, sex workers and men who have sex with men) in seven South African cities.

methodsSamples were screened on the OraQuick HCV POC test (471 whole blood and 218 oral fluid); 218 whole blood and DBS paired samples were evaluated on the ARCHITECT HCV antibody (Abbott) and HCV viral load (COBAS Ampliprep/COBAS TaqMan version 2) assays. For HCV RNA quantification, 107 dB were analyzed with and without normalization coefficients.

resultsPOC on either whole blood or oral fluid showed an overall sensitivity of 98.5% (95% CI 97.4-99.5), specificity of 98.2% (95% CI 98.8-100) and accuracy of 98.4% (95% CI 96.5-99.3). On the antibody immunoassay, DBS showed a sensitivity of 96.0% (95% CI 93.4-98.6), specificity of 97% (95% CI 94.8-99.3) and accuracy of 96.3% (95% CI 93.8-98.8). A strong correlation (

conclusionThe POC test performed sufficiently well to be used for HCV screening in at-risk populations. DBS for diagnosis and quantification was accurate and should be considered as an alternative sample to test. POC and DBS can help scale up hepatitis services in the country, in light of our elimination goals.

Indexed as

dried blood spotHCVhigh riskpoint‐of‐carescreening

Identifiers

PMID33614978
PMCPMC7876859
OpenAlexW3128219483

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.